Protocols · Regenerative
Dosage and protocol information sourced exclusively from PeptideDosages.com.
Read this first
Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.
The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.
BPC-157 · 10 mg Vial
BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols.
| Week | Daily Dose (mcg) |
|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) |
| Weeks 3–4 | 400 mcg (0.4 mg) |
| Weeks 5–8+ | 600 mcg (0.6 mg) |
5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.
| Source dose | U-100 syringe |
|---|---|
| 200 mcg | 12 units |
| 400 mcg | 24 units |
| 600 mcg | 36 units |
BPC-157 · 5 mg Vial
BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols.
| Week | Daily Dose (mcg) |
|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) |
| Weeks 3–4 | 400 mcg (0.4 mg) |
| Weeks 5–8+ | 600 mcg (0.6 mg) |
5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.
| Source dose | U-100 syringe |
|---|---|
| 200 mcg | 12 units |
| 400 mcg | 24 units |
| 600 mcg | 36 units |
Want the studies behind these figures? Read our BPC-157 tissue-repair evidence review — tendon, muscle and gut research with every source cited.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, meaning it is a chain of fifteen amino acids (PMID 40789979, PMID 40005999). It was originally isolated from gastric juice (PMID 40789979, PMID 40005999). It is known as a stable gastric pentadecapeptide (PMID 32445447, PMID 29998800). BPC-157 is currently considered investigational and has not been approved for use in standard medicine by regulatory authorities such as the FDA (PMID 40789979, PMID 40005999).
BPC-157 is reported to activate several molecular pathways in preclinical studies. These include VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, which promotes the formation of new blood vessels (angiogenesis) and fibroblast activity (PMID 40789979). It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and has anti-inflammatory effects (PMID 40789979). In cell culture, BPC-157 opposes the negative modulator 4-hydroxynonenal (HNE), reversing its growth-inhibiting effect into growth stimulation of cultured tendocytes (PMID 14554208, cell study). It also stabilizes intestinal permeability and enhances cytoprotection (PMID 32445447). BPC-157 also enhances growth hormone receptor expression (PMID 40756949, preclinical studies).
Preclinical studies have shown BPC-157 to have robust regenerative and cytoprotective effects (PMID 40789979). In various animal models, it has demonstrated regenerative properties across numerous conditions (PMID 40789979, PMID 40005999). Specifically, animal studies suggest it can improve the healing of musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries (PMID 40756949). For instance, in rats, BPC-157 improved recovery of transected Achilles tendons, leading to increased load of failure, improved function, and superior formation of fibroblasts, reticulin, and collagen (PMID 14554208, animal study). BPC-157 has also been shown to protect stomach cells and maintain gastric integrity against noxious agents like nonsteroidal anti-inflammatory drugs (NSAIDs) in animal models, and to counteract NSAID-induced gastrointestinal cytotoxicity and leaky gut syndrome (PMID 32445447, animal study).
Human data for BPC-157 is extremely limited, with only three pilot studies identified (PMID 40789979). One retrospective human study investigated intra-articular injection of BPC-157 for knee pain. In this study of 16 patients, 11 of 12 patients who received BPC-157 alone reported significant improvement in knee pain (PMID 34324435, human study). Another pilot study involved 12 women with interstitial cystitis who received intravesical BPC-157 injections. Ten patients reported complete resolution of symptoms, and the remaining two reported 80% success (PMID 39325560, human study). A pilot study also assessed intravenous safety and pharmacokinetics in humans, reporting no adverse effects (PMID 40789979). Across these limited human studies, no adverse effects have been reported (PMID 40789979, PMID 34324435, PMID 39325560).
Despite extensive preclinical support and growing public interest, there is minimal human data available (PMID 40789979). Rigorous, large-scale clinical trials are lacking to assess the safety, efficacy, and clinical utility of BPC-157 (PMID 40789979, PMID 40005999). The existing human studies are small pilot or retrospective studies, which have limitations such as varying patient follow-up and the lack of specific tools to measure functional improvement or quality of life (PMID 34324435, PMID 39325560). Preclinical safety studies have shown no adverse effects across several organ systems, but clinical safety data beyond small pilot studies are needed (PMID 40756949).
Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Verified suppliers
We are an independent publication — we sell nothing, hold no stock and take no payment. When you have finished reading, these are the suppliers we have checked for lot-matched third-party certificates of analysis.
1 · Plan the bench work
Work out reconstitution volumes and concentrations before ordering, so you buy the vial size your protocol actually needs.
Reconstitution calculator2 · Check the paperwork
Only use material released with a lot-matched third-party certificate of analysis.
Batch certificates3 · Verified suppliers
How we verify, what each supplier publishes and which regions they serve.
Supplier directoryOutbound supplier links are marked nofollow/sponsored. Compounds discussed are laboratory research reagents, not medicines. Listing is not an endorsement or medical advice.
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Biomech Peptides and Regena.app (biomechpeptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Biomech Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.
